Clinical trial
S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive…
NCT00087152 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00087152 |
|---|---|
| Title | S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer |
| Official title | Phase II Trial Of Imatinib Mesylate (Gleevec®) (NSC-716051) In Combination With Capecitabine (Xeloda®) (NSC-712807) In Metastatic Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine, Imatinib mesylate |
| Enrollment | 27 |
| Start date | Jun 1, 2004 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Jul 12, 2004 |
| Last update posted | Jun 9, 2014 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: